The distinct roles of the two estrogen receptor (ER) isotypes, ER␣ and ER␤, in mediating the physiological responses to estrogens are not completely understood. Although knockout animal experiments have been aiding to gain insight into estrogen signaling, additional information on the function of ER␣ and ER␤ will be provided by the application of isotypeselective ER agonists. Based on the crystal structure of the ER␣ ligand binding domain and a homology model of the ER␤-ligand binding domain, we have designed steroidal ligands that exploit the differences in size and flexibility of the two ligand binding cavities. Compounds predicted to bind preferentially to either ER␣ or ER␤ were synthesized and tested in vitro using radio-ligand competition and transactivation assays. This approach directly led to highly ER isotype-selective (ϳ200-fold) and potent ligands. To unravel physiological roles of the two receptors, in vivo experiments with rats were conducted using the ER␣-and ER␤-selective agonists in comparison to 17␤-estradiol. The ER␣ agonist induced uterine growth, caused bone-protective effects, reduced LH and FSH plasma levels, and increased angiotensin I, whereas the ER␤ agonist did not at all or only at high doses lead to such effects, despite high plasma levels. It can thus be concluded that estrogen effects on the uterus, pituitary, bone, and liver are primarily W ITH THE DISCOVERY of a second distinct estrogen receptor, ER␤ (1), the hope was raised that tissue-specific effects can be achieved with ER isotype-selective ligands. Subsequently, the question arose which physiological responses are attributable to either ER␣ or ER␤ or both receptors. To answer these questions, mRNA and protein expression of the receptors in numerous tissues has been studied (2-4). Dominant expression of the respective ER isotypes in certain tissues suggests a distinct physiological role. ER␣ has a broad expression pattern and is most abundant in uterus, vagina, liver, and pituitary. ER␤ is expressed in rat ovary, prostate, epididymis, lung, hypothalamus, and bladder (5). Low expression of ER␤ was observed in all uterine tissues (6).
The distinct roles of the two estrogen receptor (ER) isotypes, ER␣ and ER␤, in mediating the physiological responses to estrogens are not completely understood. Although knockout animal experiments have been aiding to gain insight into estrogen signaling, additional information on the function of ER␣ and ER␤ will be provided by the application of isotypeselective ER agonists. Based on the crystal structure of the ER␣ ligand binding domain and a homology model of the ER␤-ligand binding domain, we have designed steroidal ligands that exploit the differences in size and flexibility of the two ligand binding cavities. Compounds predicted to bind preferentially to either ER␣ or ER␤ were synthesized and tested in vitro using radio-ligand competition and transactivation assays. This approach directly led to highly ER isotype-selective (ϳ200-fold) and potent ligands. To unravel physiological roles of the two receptors, in vivo experiments with rats were conducted using the ER␣-and ER␤-selective agonists in comparison to 17␤-estradiol. The ER␣ agonist induced uterine growth, caused bone-protective effects, reduced LH and FSH plasma levels, and increased angiotensin I, whereas the ER␤ agonist did not at all or only at high doses lead to such effects, despite high plasma levels. It can thus be concluded that estrogen effects on the uterus, pituitary, bone, and liver are primarily mediated via ER␣. Simultaneous administration of the ER␣ and ER␤ ligand did not lead to an attenuation of ER␣-mediated effects on the uterus, pituitary, and liver parameters. W ITH THE DISCOVERY of a second distinct estrogen receptor, ER␤ (1), the hope was raised that tissue-specific effects can be achieved with ER isotype-selective ligands. Subsequently, the question arose which physiological responses are attributable to either ER␣ or ER␤ or both receptors. To answer these questions, mRNA and protein expression of the receptors in numerous tissues has been studied (2) (3) (4) . Dominant expression of the respective ER isotypes in certain tissues suggests a distinct physiological role. ER␣ has a broad expression pattern and is most abundant in uterus, vagina, liver, and pituitary. ER␤ is expressed in rat ovary, prostate, epididymis, lung, hypothalamus, and bladder (5) . Low expression of ER␤ was observed in all uterine tissues (6) .
In the human prostate, the majority of epithelial cells expresses ER␤, whereas the stromal cells are negative (3) . In the ovary, ER␣ expression is observed in the stromal compartment and the theca cells. Expression of ER␤ is restricted to granulosa cells of developing follicles (7) .
In addition to expression studies, the phenotypes of knockout mice in which each of the receptors or both were inactivated, have been analyzed (8) (9) (10) (11) . The resulting knockout mouse phenotypes largely reflect the mRNA expression pattern of ER␣ and ER␤. The ER␣KO mice show a severe phenotype, are infertile (male and female), display elevated LH, estradiol, and testosterone levels (female), have decreased bone density and a disturbed breast development (8) . In contrast, ER␤KO mice develop normally and do not display a severely hampered reproductive function. Consistent with the high abundance of ER␤ in the ovary, the number of ovulated oocytes is reduced (9, 11) . The prostate phenotype of these mice is still a matter of debate (3, 12) .
Further insight into ER␣ and ER␤ function has been provided by applying selective ligands to animals and studying the pharmacological effects (13) (14) (15) . Compounds described for these purposes are the ER␣-selective agonist propyl pyrazole triol (PPT) (16) , the ER␤ selective agonists diarylpropionitrile (DPN) (17) , and the benzoxazole derivative ERB-041 (15) .
In contrast to knockout animals, in which the entire receptors are inactivated throughout ontogeny and postnatal life, these experiments allow the ligand-dependent functions of both ERs and their interaction to be studied.
We have designed highly isotype-selective, steroidal ER agonists that, when applied to animals, directly stimulate either ER␣ or ER␤. In contrast to the abovementioned nonsteroidal isotype-selective ER ligands, our compounds were designed on the basis of the available protein structure information and are close derivatives of the natural hormone estradiol. We suggest that the results obtained with these tool compounds mimic the physiological situation of estrogen action and provide additional insights into ER␣ and ER␤ functions. Here we describe the structure-based design, the synthesis strategy, the in vitro compound profiling, and the in vivo pharmacological characterization of these tool compounds in female rats.
All animal procedures described here were run according to accepted standards of humane animal care, especially German animal welfare law with the permission of the District Government of Thuringia, Germany.
RESULTS

Protein Structure-Based Design of ER IsotypeSelective Ligands
Based on the crystal structure of the ligand binding domain (LBDs) of the ER␣ in complex with 17␤-estradiol (E 2 ) (18) , an ER␤ homology model was generated. The sequence alignment of the ER␣ and ER␤ LBDs shows 59% sequence identity with only two single amino acid deletions in loop regions in the case of ER␤ (Fig. 1 ). The homology model was constructed by replacing the nonidentical amino acids according to this sequence alignment and altering the protein backbone in the region of deletions. The ER␤ model is shown in Fig. 2 .
Structure-Based Design of ER␣ and ER␤-Selective Ligands
An analysis of the two receptors' ligand binding pockets [each composed of 23 amino acids in direct vicinity (4Å) to E 2 ] revealed two amino acid differences: ER␣ L384 -Ͼ ER␤ M336 and ER␣ M421 -Ͼ ER␤ I373, with (Fig. 3A) . Although the volume of the sulfur-containing methionine side chain (volume ϭ 85.9 Å 3 ) is slightly larger than the branched amino acid side chains of leucine and isoleucine (volume ϭ 82.6 Å 3 resp. 82.3 Å 3 ), it was predicted that the increased flexibility of the linear methionine side chain would allow larger substituents to be accommodated. Thus, substitution of E 2 with lipophilic groups containing one or two heavy atoms in 8␤ position was predicted to lead to highly selective ER␤ agonists. These compounds would fit well into the ER␤ ligand binding pocket (Fig. 3C ), although colliding with L384 in the case of ER␣. Similarly, a substitution at position 16␣ and/or 17␣ would lead to ER␣ agonists. Again a larger substituent would replace the flexible methionine (ER␣-M421, Fig. 3B ), although it interacts unfavorably with the rigid isoleucine (ER␤ I373) below the steroidal D-ring.
Synthesis Strategy of ER␣-and ER␤-Selective Ligands
Guided by the structure-based design, modifications of E 2 at the respective positions were realized using chemical synthesis (Fig. 4) . To obtain ER␣-selective compounds, E 2 was substituted with a five-membered ring bridging positions 16␣ and 17␣. This additional cyclic ether (compound 1) or lactone ring (compound 2: 3,17-dihydroxy-19-nor-17␣-pregna-1,3,5(10)-triene-21,16␣-lactone, named 16␣-LE 2 ), respectively, provides bulkiness below the D-ring Figs. 3B and 4).
ER␤-selective ligands were obtained by substituting E 2 above the B-and C-ring, corresponding to position 8␤. Two selected compounds bearing a methyl (compound 3) and a vinyl group (compound 4: 8-vinylestra-1,3,5(10)-triene-3,17␤-diol, named 8␤-VE 2 ) are given here. The 8-subsitutent provides additional lipophilic space to explore the few differences between the ER␣ and ER␤ binding pockets (Figs. 3D and 4). The synthesis of the compounds is described in patent applications (19, 20) and will be published in detail elsewhere.
In Vitro Characterization of ER Isotype-Selective Ligands
The affinity of the synthetic ligands to rat (r) ER and human (h) ER ␣ and ␤ and the induction of reporter gene The two amino acids in the binding cavity that differ between hER␣ and hER␤ (ER␤-M336 and ER␤-I373) are drawn in black. transcription via hER␣ and ER␤ were determined using competitive radiometric and transactivation assays.
Compounds with larger substituents in positions 16␣ and 17␣ (compounds 1 and 2) show a high affinity for rER␣ and hER␣, whereas they bind to rER␤ and hER␤ with an affinity about 2 orders of magnitude lower (Table 1) . More polar and larger substituents increase the ER␣ selectivity. Similar results are obtained with transactivation experiments, indicating a 250-fold selectivity in reporter gene activation via ER␣ for 16␣-LE 2 (Table 1 and Fig. 5 ).
As predicted from the homology models, larger substituents in position 8␤ increase ER␤ selectivity. 8␤-VE 2 is characterized by a similar affinity to rER␤ and hER␤ as E 2 , whereas binding to rER␤ and hER␤ occurs at concentrations that are more than 2 orders of magnitude lower ( Table 1 ). The latter compound displays a 183-fold ER␤ selectivity in the transactivation assay (Table 1) .
Neither 8␤-VE 2 nor 16␣-LE 2 exhibit antagonistic activity on E 2 -induced reporter gene activity in ER␣ and ER␤-dependent transactivation assays (data not shown). In these experiments, the pure antiestrogen ZM 182780 was used as a reference and caused halfmaximal inhibition of the E 2 -induced reporter gene activity at concentrations of 1-3 nmol/liter.
In Vivo Characterization of ER Isotype-Selective Ligands
E 2 and 16␣-LE 2 caused a dose-dependent increase in uterine weight, dose-dependent decreases in serum rFSH and rLH (Fig. 6 ). 8␤-VE 2 affected uterine weight and rLH only at the highest dose tested (100 g/ animal⅐d) and had no effect on rFSH in plasma (Fig. 6) . Regarding hepatic estrogenicity, E 2 caused a slight increase in angiotensinogen as measured by its enzymatic reaction product angiotensin I at a dose of 100 g/animal⅐d. 16␣-LE 2 exhibited considerable hepatic estrogenicity. A dose-dependent increase in angiotensin I (Fig. 6 ) and decreases in IGF-I, high-density lipoprotein (HDL), and total cholesterol were observed. 8␤-VE 2 had no effect on any of these parameters. The A schematic representation of the side-view of the steroids is given along with the numbering of the steroidal rings. The volume above the C-and D-rings corresponds to the 18-methyl group of E 2 . Bulky substitution below the D-ring leads to ER␣ agonists, whereas lipophilic substitution above the Band C-ring gives ER␤-agonists. (n ϭ 2) (n ϭ 3) (n ϭ 3) (n ϭ 9) (n ϭ 9)
Relative binding affinities (RBA) and relative transcritional potencies (RTP) are given in percentage, with E 2 being set to 100% binding and transactivation via rat (rER␣ or rER␤) or human (hER␣ or hER␤) ERs. Values are given as mean value Ϯ SD (number of experiments in parentheses).
bone mineral density (BMD) in the ovariectomized (OVX) model is fully recovered by treatment with E 2 (1 g/animal⅐d) or 16␣-LE 2 at 10 g/animal⅐d (Fig. 7) . In case of the ER␤ agonist, significant effects were observed only at the highest dose (100 g/animal⅐d). This dose restored 78% of BMD. In agreement with the effects on bone density, E 2 and 16␣-LE 2 caused significant decreases in deoxypyridinoline (DPD) and hydroxyproline levels (Fig. 7) at the 0.1 and 1 g/animal⅐d doses, respectively, whereas the 8␤-VE 2 caused a slight effect only at 100 g/animal⅐d or was inactive. Assuming that ER␤ might exert an inhibitory effect on ER␣ transactivational activity (21), we tested various combinations of both tool compounds in vivo. No signs of inhibition of ER␣ effects by the ER␤ ligand were observed on uterine weight (Fig. 8) , rFSH, rLH, angiotensin I, IGF-I, HDL, and total cholesterol (data not shown).
8␤-VE 2 serum levels were determined after sc administration using a specific RIA and found to be 0.8 ng/ml for the 10 g/animal dose and 5.9 ng/ml for the 100 g/animal dose (see supplemental data published on The Endocrine Society's Journals Online web site at http://mend.endojournals.org).
DISCUSSION
Structure-Based Design of ER Isotype-Selective Agonists
The availability of structural information on an interesting drug target protein has led to the prediction and identification of highly potent and selective ligands. The three-dimensional protein structure information, based on a homology model rather than an experimental structure, provided a solid basis for ligand synthesis strategy. A comparison of the x-ray structure of the ER␤-LBD in complex with genistein (22) published after starting the work described here with our homology model, reveals that the model shows a root-meansquare deviation of the backbone atoms [not considering helix 12 (H12)] of 1.4 Å. The structure of the protein core (including the ligand binding pocket) in the model is thus nearly identical with the x-ray struc- ture (22) . The position of H12 was modeled in the agonistic conformation as described for the hPR (human progesterone receptor)-LBD (23) and hER␣-LBD (24) . Interestingly, the predicted flexibility of the methionine ER␤-M336 was observed experimentally in the ER␤ LBD-genistein complex x-ray structure. This side chain adopts two unequally (70:30) occupied alternative positions, indicating high flexibility. In another homology model of ER␤ (25) , it was predicted that the ER␤ ligand binding pocket at the ␤-face of E 2 is smaller due to the bulkier side chain of methionine (ER␤-M336) in comparison to leucine (ER␣-L384). Indeed, it was confirmed in the ER␤ x-ray structure that the ligand binding cavity is smaller than in the case of ER␣. However, the prediction that substitution at the ␤-face of E 2 (positions 8␤ and 15␤) should result in ER␣-selective compounds and substitution at the ␣-face (positions 16␣ and 17␣) should yield ER␤-selective compounds (25) is not supported by our studies. Although methionine is slightly larger than leucine and isoleucine, we considered it to be more flexible, leading to the prediction that larger substituents can be accommodated in the vicinity of methionine residues. The in vitro test results of the isotype-selective ligands support this prediction and demonstrate the importance of considering protein (side chain) flexibility in view of designing ligands. Studies involving the systematic derivatization of hexestrol have resulted in DPN, another highly ER␤ selective agonist (17) . Sitedirected mutagenesis and transactivation studies also suggest that the difference in size of the ER␣/␤ binding pockets due to the difference ER␣-L384/ER␤-M336 is responsible for the high isotype selectivity of DPN (26) . It has recently been shown that single point mutations of those amino acids that differ between ER␣ and ER␤ alone cannot account for the ER␣ selectivity of PPT and that long-range interactions have to be taken into consideration (27) . This may be explained by the completely different structure of PPT in comparison to estradiol. Certain conformational rearrangements within the ligand binding pocket must occur to accommodate PPT (16) . This is in contrast to our ligands, which are designed to be structurally close to 17␤-estradiol and effectively exploit the few differences within the binding pockets with only relatively small substituents. It is thus supposed that our ligands do not induce larger conformational rearrangements within the binding pockets with respect to 17␤-estradiol and that ligand selectivity is not dependent on long-range interactions.
In Vitro Studies
Because ER␣ is the predominat ER isotype in the uterus, and ER␤ shows high expression levels in prostate, estrogen isotype-selective compounds could be identified using preparations of these tissues for receptor binding studies. The results obtained with the rat cytosolic preparations correlate with the relative binding affinities determined with in vitro-expressed hERs ( Table 1 ). The binding affinities also agree with the transactivation data obtained with cell-based reporter gene assays (Table 1) . Especially in the case of the ER␤-selective agonists (compound 3 and 4), a correlation between ligand binding and reporter gene transcription was obtained. 16␣-LE 2 and 8␤-VE 2 are thus estrogens that bind to and act on ER␣ and ER␤ selectively but with a similar potency as E 2 .
In Vivo Studies: Selective Activation of ER␣ or ER␤
The compounds 16␣-LE 2 and 8␤-VE 2 appear excellently suited for the study of ER␣/␤-mediated functions because they act on either ER␣ or ER␤ with a comparable selectivity and are nearly equally potent with respect to E 2 . In addition, both compounds are close steroidal analogs of E 2 (only two to four additional carbon/oxygen atoms) and thus reduce the probability of completely different biological activities at other receptors or enzymes with respect to 17␤-estradiol. Genistein for example, also described as weakly selective ER␤-ligand (28, 29) , is characterized by inhibition of tyrosine kinases (30), 17␤-hydroxysteroid dehydrogenases, and 5␣-reductase type II (31) . It is as such not very well suited for studying ER isotype-mediated effects in in vivo models. A notable difference between the ER␣ and ER␤ agonists is the substitution of position 17␣ in case of 16␣-LE 2 , which protects this compound against oxidation of the 17␤-hydroxy group through 17␤-hydroxysteroid dehydrogenases. 8␤-VE 2 is not protected and was supposed to be metabolically less stable. The compounds were thus administered sc with osmotic pumps, leading to high plasma levels (see supplemental data on The Endocrine Society's Journals Online web site at http://mend.endojournals.org).
The results of the in vivo studies with the steroidal ER␣ and ER␤ ligands are in agreement with expectations based on the tissue distribution of ER␣ and ER␤, respectively, and ER knockout phenotypes. Organs expressing predominantly ER␣ such as uterus, pituitary, and liver could be affected with E 2 and 16␣-LE 2 , but not (or only at the highest dose) with 8␤-VE 2 . At this high dose, the residual ER␣ activity of 8␤-VE 2 (Table 1 ) is presumed to be responsible for the observed effects. The uterotropic activity of E 2 as well as the feedback via the hypothalamic-pituitary axis is thus mediated predominantly via ER␣ (Fig. 6) . Similar results were obtained with the ER␣-selective agonist PPT (13) . ER␤ plays an inferior role in these organs. Interestingly, the effects on hepatic parameters such as angiotensin I, IGF-I, HDL, and total cholesterol are stronger for 16␣-LE 2 than for E 2 . The ER␤ agonist did not show effects on these parameters up to 100 g/ animal⅐d (Fig. 6 ). Liver effects are thus mediated via ER␣. It is well known that 17␣-alkyl-substituted steroids (like 16␣-LE 2 or ethinylestradiol) are protected against oxidation of the 17␤-hydroxy group, a keystep in metabolic inactivation of steroidal estrogens. The metabolic stabilization through the substitution would impair metabolic inactivation and contribute to the substantial hepatic estrogenicity of the ER␣ agonist (32) . Protection against OVX-induced bone loss by 16␣-LE 2 confirms that ER␣ is the primary mediator of antiresorptive effects of estrogens on bone and are consistent with observations made with the ER␣ agonist PPT (13) . In trabecular bone, ER␣ and ER␤ are coexpressed, although ER␣ is about 10-fold more abundant than ER␤ at the mRNA level (33) . 16␣-LE 2 was 10 times less potent than E 2 in preventing the OVX-induced loss of BMD, whereas 8␤-VE 2 was 1000-fold less potent than E 2 . Bone-protective effects of 8␤-VE 2 at very high doses appear to be mediated via ER␣. Several surrogate parameters for bone effects such as DPD and hydroxyproline (Fig. 7 ) are in agreement with the BMD measurements. DPD and hydroxyproline, markers that reflect the amount of degraded collagen, are significantly decreased with E 2 and 16␣-LE 2 treatment but not with 8␤-VE 2 . Interestingly, throughout all in vivo experiments, the effects of 16␣-LE 2 on uterus, pituitary, bone, and liver occur at doses that are slightly more than 2 orders of magnitude, but significantly less than 3 orders of magnitude lower than in the case of the ER␤ agonist. This ratio (ER␣/ER␤) of more than 100-fold in the in vivo experiments reflects the selectivity of 16␣-LE 2 determined in vitro (70-to 250-fold; Table 1 ). Also a comparison between the in vitro and in vivo potency of the ER␣ agonist and E 2 reveals a good agreement between the two methods.
It has been suggested that ER␤ reduces ER␣-mediated gene transcription, also referred to as a "Yin Yang" relationship (21) . The availability of the two ER isotype-selective agonists permitted us to test this hypothesis. The simultaneous administration of 16␣-LE 2 and 8␤-VE 2 did not result in inhibition of ER␣-mediated effects on uterine weight (Fig. 8) , pituitary (rFSH, rLH, data not shown), and liver (angiotensin I, IGF-I, HDL, and total cholesterol, data not shown). At least in these organs, the ER␤ agonist was unable to antagonize ER␣ effects.
In all the in vivo experiments discussed, low serum levels of 8␤-VE 2 cannot explain weak or undetectable effects of 8␤-VE 2 on estrogen-sensitive parameters. At nonuterotropic doses (e.g. 10 g/animal⅐d), plasma levels as high as 0.8 ng/ml (see supplemental data on The Endocrine Society's Journals Online web site at http://mend.endojournals.org) were found. In comparison, E 2 exerts its effects at plasma levels of 5-40 pg/ml (34) . Indeed, we and others (15, 35) recently revealed distinct physiological roles that are solely mediated via ER␤ using ER isotype selective compounds.
The work presented here demonstrates that it is possible to use protein structure information, either from an x-ray structure or a homology model, to design receptor isotype-selective ligands and to apply such compounds as pharmacological tools in animal models for studying the physiological roles of the respective receptors. The results of the in vivo studies with the ER isotype-selective compounds described here illustrate that reproductive and metabolic estrogen effects are mediated via ER␣. The described tool compounds are suitable for studying estrogen effects in variety of other tissues, organs, and species.
MATERIALS AND METHODS
Homology Modeling and Structure-Based Ligand Design
The full-length sequences of all human steroid hormone receptors (ER␣ and ␤, androgen, glucocorticoid, mineralocorticoid, and PR) were aligned using the program ClustalW (36) . Gonnet series matrices and gap opening/gap extension penalties of 10/0.2 were used. The homology model of ER␤ was built based on the crystal structure of ER␣ (18) . Because H12 of the ER␣-LBD forms contacts with a neighboring protein molecule in this crystal structure, a conformation of this helix similar to H12 in the PR-LBD was modeled. This model of ER␣ was used as a template for the construction of the ER␤ model, using the SYBYL program (Tripos Inc., St. Louis, MO). Energy minimization with the AMBER 4.1 force field led to the final model of ER␤. A detailed description of the homology modeling procedure is given in (37) . Volume calculations of amino acids were performed with MOLCAD in SYBYL. All four ER isotype-selective agonists were manually placed into the binding pockets by superimposition with estradiol and subsequently docked by energy minimization using the MMFF94 force field (38) .
ER Binding Studies
The binding affinity of the compounds to rER␣, rER␤, hER␣, and hER␤ were determined by in vitro competition experiments using [ 3 H]E 2 (5 nmol/liter) as a ligand and unlabeled E 2 as a reference (39) . hER␣ and hER␤ were produced in Sf9 insect cells using baculovirus expression vectors (an expression plasmid for the hER␣ was obtained from P. Chambon, Strasbourg, France). Ligand binding to rER␣ and rER␤ was determined using cytosol preparations (40) of rat prostate (41) and rat uterus (42) . The binding affinity of the test compounds is given as relative binding affinity, defined as (IC 50 E 2 /IC 50 test compound) ϫ 100 (IC 50 of E 2 is 5 nmol/liter), whereby the IC 50 of E 2 at hER␣ equals 1.25 Ϯ 0.7 ϫ 10
Ϫ8
(n ϭ 4) and the IC 50 of E 2 at hER␤ equals 1.32 Ϯ 0.7 ϫ 10
(n ϭ 4).
Transactivation Assays
The estrogenic potency of the ER ligands in vitro was determined by transactivation assays (39) . U2-OS human osteosarcoma cells (ATCC, Manassas, VA) were transiently cotransfected with hER␣ or hER␤ expression vector (hER␣: HEGO, P. Chambon), respectively, and an estrogen response element (ERE) 2 -luciferase reporter gene. Estrogen-induced reporter gene activity was determined 24 h after treatment of the cells with test compounds. The relative transcriptional potency is defined as (EC 50 E 2 /EC 50 test compound) ϫ 100 (EC 50 of E 2 ϭ 4.5 Ϯ 1.6 ϫ 10 Ϫ12 M (n ϭ 8) in the ER␣ transactivation assay and EC 50 of E 2 ϭ 3.3 Ϯ 1.4 ϫ 10 Ϫ11 M (n ϭ 8) in the ER␤ transactivation assay).
Animal Studies
Effect of 16␣-LE 2 and 8␤-VE 2 on uterus, pituitary, and liver. Adult OVX Wistar rats (body weight 220-250 g) were treated for 8 d with E 2 , 16␣-LE 2 , 8␤-VE 2 , or vehicle (propylene glycol) starting 21 d after surgery. Osmotic pumps (Alzet, model 2001D) for sc treatment. Parameters determined were as follows: uterine weight; rFSH, rLH, angiotensin I, IGF-I, HDL, total cholesterol, and plasma levels of 8␤-VE 2 . Effect of 16␣-LE 2 and 8␤-VE 2 on bone. Six-month-old Wistar rats (body weight 250-270 g) were OVX and immediately treated for 29 d with E 2 , 16␣-LE 2 , 8␤-VE 2 , or vehicle (propylene glycol). The compounds were administered sc by osmotic pumps (Alzet, model 2004). Urine was collected on d 1, 8, and 29; blood on d 1, 8, 15, and 29. IGF-I, rGH, angiotensin I, HDL, total cholesterol, hydroxyproline, and DPD cross-links were determined. On d 29, the animals were killed, and uteri and tibiae were prepared. BMD was measured using quantitative x-ray computer tomography. Coadministration of 16␣-LE 2 and 8␤-VE 2 . On d 14 after OVX, Wistar rats (body weight 180-200 g) were treated sc for 3 d with 16␣-LE 2 , 8␤-VE 2 , combinations of 8␤-VE 2 plus 16␣-LE 2 or vehicle alone (benzyl benzoate ϩ castor oil: 1 ϩ 4 vol/vol). Uterine weight, rFSH, rLH, IGF-I, HDL, total cholesterol, and angiotensin I were determined.
